In early 2019, Martin Gottesfeld of Anonymous was sentenced under America’s “Computer Fraud and Abuse Act” to 10 years in federal prison for his alleged role in the 2014 DDoS attacks on healthcare and treatment facilities around Boston. (Gottesfeld was sentenced by the same judge who oversaw the Aaron Swartz case.)

Gottesfeld has just filed his first appeal, and Slashdot reader Danngggg shares this new interview with Gottesfeld’s attorney Brandon Sample. The upshot?
Brandon Sample: If the court agrees with our arguments, for example, on the Speedy Trial Act, then that would result in dismissal of the indictment against him. And so, he would have no conviction at that point. There’s a variety of different outcomes that could potentially flow from the arguments that have been raised in the appeal. If he wins, say for example, the argument that his lawyer should have been allowed off the case, well, then that would undo the conviction as well, and he would be entitled to another trial.

If the indictment is dismissed, then the government is going to have to make a decision about whether or not this is really a case that they want to prosecute all over again…

Daily Wire: Do you see this being successful, a strong case?
Brandon Sample: The appeal? I think we have a really good chance. I do.

Read more of this story at Slashdot.

Source: Slashdot – Imprisoned ‘Anonymous’ Hacktivist Martin Gottesfeld Files His First Appeal

Newsweek reports:
Pharmaceutical manufacturer Johnson & Johnson announced Friday that early trials of a COVID-19 vaccine showed a 98 percent success rate in showing a boost in the immune system. According to research from Johnson & Johnson, the vaccine enabled 98 percent of those who took it to create antibodies that fight off the coronavirus infection. Those neutralizing antibodies were present 29 days after receiving the vaccination…

Currently, four U.S. vaccines are in the final trial stages. Vaccines from other pharmaceutical companies such as Pfizer and Moderna are administered in two doses while the Johnson & Johnson vaccine only requires one.
“Based on the current results, Johnson & Johnson on Wednesday kicked off a final 60,000-person trial,” reports Reuters, “which could pave the way for an application for regulatory approval. The company said it expects results of that so-called Phase 3 trial by the end of the year or early next year.”

Read more of this story at Slashdot.

Source: Slashdot – Johnson & Johnson’s Covid-19 Vaccine Produces Strong Immune Response in Early Trial

The New York Times reports:
Vaccine maker Novavax said Thursday that it would begin the final stages of testing its coronavirus vaccine in the United Kingdom and that another large trial was scheduled to begin next month in the United States. It is the fifth late-stage trial from a company supported by Operation Warp Speed, the federal effort to speed a coronavirus vaccine to market, and one of 11 worldwide to reach this pivotal stage.

Novavax, a Maryland company that has never brought a vaccine to market, reached a $1.6 billion deal with the federal government in July to develop and manufacture its experimental vaccine, which has shown robust results in early clinical trials. The new study, known as a Phase 3 trial, is expected to enroll up to 10,000 people in the United Kingdom. Half of the volunteers will receive two doses of the experimental vaccine, 21 days apart, and the others will receive a placebo.

Although Novavax is months behind the front-runners in the vaccine race, independent experts are excited about its vaccine because its early studies delivered particularly promising results. Monkeys that were vaccinated got strong protection against the coronavirus. And in early safety trials, published early this month in The New England Journal of Medicine, volunteers produced strikingly high levels of antibodies against the virus. It is not possible to make a precise comparison between early clinical studies of different vaccines, but John Moore, a virologist at Weill Cornell Medicine, said that the antibodies from Novavax were markedly higher than any other vaccine with published results. “You just can’t explain that away,” he said. The Phase 3 trials will determine if Novavax can live up to that promise.

Read more of this story at Slashdot.

Source: Slashdot – Vaccine Maker Novavax Enters Final Large-Scale Testing of Its Covid-19 Vaccine

LWN.net re-visits the emacs-devel mailing list, where the Emacs 28 development cycle has revived discussions about how to make the text editor more “modern” and attractive to new users:

A default dark theme may not be in the future, leading one to think that there may yet be hope for the world in general. But there does seem to be general agreement that Emacs could benefit from a better, more centralized approach to color themes, rather than having color names hard-coded throughout various Elisp packages. From that, a proper theme engine could be supported, making dark themes and such easily available to those who want them…
Another area where Emacs is insufficiently “modern”, it seems, has to do with keyboard and mouse bindings. On the keyboard side, users have come to expect certain actions from certain keystrokes; ^X to cut a selection, ^V to paste it, etc. These bindings are easily had by turning on the Cua mode, but new users tend not to know about this mode or how to enable it. Many participants in the discussion said that this mode should be on by default. That, of course, would break the finger memory of large numbers of existing Emacs users, who would be unlikely to appreciate the disruption. Or, as Richard Stallman put it:

It is not an option to change these basic key bindings to imitate other, newer editors. It would create a different editor that we Emacs users would never switch to. It is unfortunate that the people who implemented the newer editors chose incompatibility with Emacs….

The situation with mouse behavior is similar; as several participants in the discussion pointed out, users of graphical interfaces have come to expect that a right-button click will produce a menu of available actions. In Emacs, instead, that button marks a region (“selection”), with a second click in the same spot yanking (“cutting”) the selected text. Many experienced Emacs users have come to like this behavior, but it is surprising to newcomers. The right mouse button with the control key held down does produce a menu defined by the current major mode, but that is evidently not what is being requested here; that menu, some say, should present global actions rather mode-specific ones.

Stallman suggested offering a “reshuffled mode” that would bring the context menu to an unadorned right-button click, and which would add some of the expected basic editing commands there as well. This would be relatively easy to do, he said, since mouse bindings are separate from everything else. Besides, as he noted, the current mouse behavior was derived from “what was the standard in X Windows around 1990”; while one wouldn’t want to act in haste, it might just be about time for an update.
Other proposed changes involved “discoverability,” including the default enabling of various modes, although to incorporate them into GNU Emacs “would often require the author to sign copyrights over to the Free Software Foundation, which is not something all authors are willing to do…”

Read more of this story at Slashdot.

Source: Slashdot – Emacs Developers (Including Richard Stallman) Discuss How to Build a More ‘Modern’ Emacs